REFERENCES
1. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202-9.
2. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999-2014.e1.
3. Rinella ME, Lazarus JV, Ratziu V, et al. ; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542-56.
4. Huang DQ, Wong VWS, Rinella ME, et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025;11:14.
5. Kim Y, Park Y, Rho H, Yao T, Gao B, Hwang S. Inflammation in MASLD progression and cancer. JHEP Rep. 2025;7:101414.
6. Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31:S32-50.
7. Zhang X, Lau HC, Yu J. Pharmacological treatment for metabolic dysfunction-associated steatotic liver disease and related disorders: current and emerging therapeutic options. Pharmacol Rev. 2025;77:100018.
8. Lin H, Lee HW, Yip TC, et al. ; VCTE-Prognosis Study Group. Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease. JAMA. 2024;331:1287-97.
9. Zhou XD, Kim SU, Yip TC, et al. ; VCTE-Prognosis Study Group. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease. Gut. 2024;73:1883-92.
10. Liu WY, Huang S, Ji H, et al. ; VCTE-Prognosis Study Group. From “Burnt-Out” to “Burning-Out”: capturing liver fat loss in patients with advanced metabolic dysfunction-associated steatotic liver disease from a dynamic perspective. Gastroenterology. 2025;169:326-36.e4.
11. Feng G, Wong VW, Targher G, Byrne CD, Zheng MH. Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring. Gut. 2025;74:1741-50.
12. Lam SM, Wang Z, Song JW, et al. Non-invasive lipid panel of MASLD fibrosis transition underscores the role of lipoprotein sulfatides in hepatic immunomodulation. Cell Metab. 2025;37:69-86.e7.
13. Younossi ZM, de Avila L, Petta S, et al. ; Global NASH/MASH Council (GNC). Global performance of non-invasive tests in MASLD: insights from the G-MASLD study. Hepatology. 2026;84:161-74.
14. Choi J, Nguyen VH, Przybyszewski E, et al. Statin use and risk of hepatocellular carcinoma and liver fibrosis in chronic liver disease. JAMA Intern Med. 2025;185:522-30.
15. Lai JC, Yang B, Lee HW, et al. Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease. Gut. 2025;74:2050-7.
16. van Kleef LA, Strandberg R, Pustjens J, et al. FIB-4-based referral pathways have suboptimal accuracy to identify increased liver stiffness and incident advanced liver disease. Clin Gastroenterol Hepatol. 2026;24:733-42.
17. Chang KC, Lin TT, Wang TC, et al. Fibrosis-4 index reflects the severity of tricuspid regurgitation and patient prognosis in atrial fibrillation. Eur J Heart Fail. 2025;27:2292-300.
18. Mózes FE, Lee JA, Vali Y, et al. ; LITMUS investigators. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8:704-13.
19. Zhou XD, Li YT, Kim SU, et al. ; VCTE-Prognosis Study Group, Paired Liver Biopsy Group. Longitudinal changes in fibrosis markers: monitoring stiffness/fibrosis progression and prognostic outcomes in MASLD. Clin Gastroenterol Hepatol. 2026;24:394-406.
20. Huang Q, Qadri SF, Bian H, et al. A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease. J Hepatol. 2025;82:781-93.
21. Sakane S, Hikita H, Shirai K, et al. Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLD. Hepatol Commun. 2024;8:e0448.
22. Serra-Burriel M, Juanola A, Serra-Burriel F, et al. ; LiverScreen Consortium Investigators. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study. Lancet. 2023;402:988-96.
23. Lindvig KP, Thorhauge KH, Hansen JK, et al. Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study. Lancet Gastroenterol Hepatol. 2025;10:55-67.
24. Cheung CY, Wan P, Wan H, et al. Development and clinical validation of a novel protein biomarkers-based algorithm for risk prediction and diagnosis of advanced liver fibrosis: a multi-centre study. J Adv Res. 2026;84:871-81.
25. Ishiba H, Fujii H, Kamada Y, et al. ; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Accuracy of type IV collagen 7S versus Enhanced Liver Fibrosis score for diagnosing fibrosis in patients with metabolic dysfunction-associated steatotic liver disease. Hepatol Commun. 2025;9:e0563.
26. Younossi ZM, Felix S, Jeffers T, et al. Performance of the enhanced liver fibrosis test to estimate advanced fibrosis among patients with nonalcoholic fatty liver disease. JAMA Netw Open. 2021;4:e2123923.
27. Kjaergaard M, Lindvig KP, Thorhauge KH, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol. 2023;79:277-86.
28. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut. 2010;59:1245-51.
29. Eslam M, Wong GL, Hashem AM, et al. A sequential algorithm combining ADAPT and liver stiffness can stage metabolic-associated fatty liver disease in hospital-based and primary care patients. Am J Gastroenterol. 2021;116:984-93.
30. Tang LJ, Ma HL, Eslam M, et al. Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. Metabolism. 2022;128:154958.
31. Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73:691-702.
32. Gellert-Kristensen H, Richardson TG, Davey Smith G, Nordestgaard BG, Tybjaerg-Hansen A, Stender S. Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population. Hepatology. 2020;72:845-56.
33. Urias E, Tedesco NR, Burkholder DA, et al. PNPLA3 risk allele is associated with risk of hepatocellular carcinoma but not decompensation in compensated cirrhosis. Hepatol Commun. 2024;8:e0441.
34. Petta S, Armandi A, Bugianesi E. Impact of PNPLA3 I148M on clinical outcomes in patients with MASLD. Liver Int. 2025;45:e16133.
35. Kozlitina J, Sookoian S. Global epidemiological impact of PNPLA3 I148M on liver disease. Liver Int. 2025;45:e16123.
36. Souza M, Al-Sharif L, Diaz I, Mantovani A, Villela-Nogueira CA. Global epidemiology and implications of PNPLA3 I148M variant in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. J Clin Exp Hepatol. 2025;15:102495.
37. Grimaudo S, Pipitone RM, Pennisi G, et al. Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2020;18:935-44.e3.
38. Kanda T, Sasaki-Tanaka R, Abe H, et al. Polygenic risk score for metabolic dysfunction-associated steatotic liver disease and steatohepatitis: a narrative review. Int J Mol Sci. 2025;26:5164.
39. Vilar-Gomez E, Yates KP, Kleiner DE, et al. Genetic and non-genetic drivers of histological progression and regression in MASLD. J Hepatol. 2026;84:502-16.
40. Xiao L, Li Y, Hong C, et al. Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes. J Transl Med. 2024;22:650.
41. Bianco C, Jamialahmadi O, Pelusi S, et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol. 2021;74:775-82.
42. Pelusi S, Baselli G, Pietrelli A, et al. Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease. Sci Rep. 2019;9:3682.
43. Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009;51:1061-7.
44. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082-90.
45. Borges VF, Diniz AL, Cotrim HP, Rocha HL, Andrade NB. Sonographic hepatorenal ratio: a noninvasive method to diagnose nonalcoholic steatosis. J Clin Ultrasound. 2013;41:18-25.
46. Hamadouche M, Vilgrain V, Hobeika C, et al. Ultrasound hepatorenal index for the diagnosis of steatosis in patients with type 2 diabetes: a prospective validation study. Eur Radiol. 2025;35:7927-39.
47. Marshall RH, Eissa M, Bluth EI, Gulotta PM, Davis NK. Hepatorenal index as an accurate, simple, and effective tool in screening for steatosis. AJR Am J Roentgenol. 2012;199:997-1002.
48. Hidaka H, Uojima H. Ultrasonography in the diagnosis of complications in patients with portal hypertension. J Med Ultrason. 2022;49:347-58.
49. Caussy C, Vergès B, Leleu D, et al. Screening for metabolic dysfunction-associated steatotic liver disease-related advanced fibrosis in diabetology: a prospective multicenter study. Diabetes Care. 2025;48:877-86.
50. Marti-Aguado D, Carot-Sierra JM, Villalba-Ortiz A, et al. Identification of candidates for MASLD treatment with indeterminate vibration-controlled transient elastography. Clin Gastroenterol Hepatol. 2025;23:1183-93.e5.
51. Zhou XD, Chen QF, Kim SU, et al. Long-term glycemic control and the risk of liver stiffness progression and liver-related events in MASLD. Clin Gastroenterol Hepatol. 2026;24:1332-43.
52. Feng G, Boursier J, de Saint Loup M, et al. ; VCTE-Prognosis Study Group, Paired Liver Biopsy Group. Fibrotic MASH resolutionVCTE index to diagnose fibrotic MASH resolution and predict LREs: a global multicenter study. Med. 2026;7:100929.
53. Boursier J, Hagström H, Ekstedt M, et al. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. J Hepatol. 2022;76:1013-20.
54. Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156:1264-81.e4.
55. Gawrieh S, Vilar-Gomez E, Wilson LA, et al. ; NASH Clinical Research Network. Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD. J Hepatol. 2024;81:600-8.
56. John BV, Bastaich DR, Deng Y, Singal AG, Dahman B; Veterans Analysis of Liver Disease (VALID) group of investigators. Use of liver stiffness measurement for HCC risk stratification in metabolic dysfunction-associated steatotic liver disease. Hepatology. 2026;83:1456-68.
57. Fichez J, Mouillot T, Vonghia L, et al. Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trials. JHEP Rep. 2025;7:101351.
58. Feng G, Mózes FE, Ji D, et al. acFibroMASH index for the diagnosis of fibrotic MASH and prediction of liver-related events: an international multicenter study. Clin Gastroenterol Hepatol. 2025;23:785-96.
59. Kirsztajn GM, Samaan F, Calice-Silva V, Pecoits-Filho R. Critical analysis of the estimated glomerular filtration rate. J Bras Nefrol. 2025;47:e20250107.
60. Levey AS, Titan SM, Powe NR, Coresh J, Inker LA. Kidney disease, race, and GFR estimation. Clin J Am Soc Nephrol. 2020;15:1203-12.
61. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII - renewing consensus in portal hypertension. J Hepatol. 2022;76:959-74.
62. Wong YJ, Chen VL, Abdulhamid A, et al. Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patients. Hepatology. 2025;81:523-31.
63. Ajmera VH, Liu A, Singh S, et al. Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease. Hepatology. 2020;71:849-60.
64. Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152:598-607.e2.
65. Hsu C, Caussy C, Imajo K, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol. 2019;17:630-7.e8.
66. Ajmera V, Kim BK, Yang K, et al. Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants. Gastroenterology. 2022;163:1079-89.e5.
67. Noureddin N, Ajmera V, Bergstrom J, et al. MEFIB-Index and MAST-Score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease-Individual participant data meta-analyses. Aliment Pharmacol Ther. 2023;58:856-65.
68. Castera L, Garteiser P, Laouenan C, et al. ; QUID NASH investigators. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes. J Hepatol. 2024;81:195-206.
69. Eslam M, Fan JG, Yu ML, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatol Int. 2025;19:261-301.
70. Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161:1657-69.
71. Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review. Gastroenterology. 2023;165:1080-8.
72. Yip TC, Lee HW, Lin H, et al. Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2025;83:304-14.
73. Lee HW, Lee JS, Kim MN, et al. Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31:1018-31.
74. Chen Y, Dong B, Jin X, et al. ; DiabetesLiver Integrated Management (DLIM) Consortium. Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes. Gut. 2026;75:576-87.
75. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138-53.
76. Thomas JA, Kendall BJ, Dalais C, Macdonald GA, Thrift AP. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Cancer. 2022;173:250-62.
77. Lee HH, Lee HA, Kim EJ, et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. 2024;73:533-40.
78. Moon JH, Jeong S, Jang H, Koo BK, Kim W. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study. EClinicalMedicine. 2023;65:102292.
79. Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovasc Diabetol. 2024;23:346.
80. Simon TG, Roelstraete B, Hagström H, Sundström J, Ludvigsson JF. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut. 2022;71:1867-75.
81. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335-47.
82. Zhang J, Li L, Lin L, et al. Prognostic value of FIB-4 and NFS for cardiovascular events in patients with and without NAFLD. BMC Public Health. 2025;25:2747.
83. Cardoso CRL, Villela-Nogueira CA, Leite NC, Salles GF. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study. Cardiovasc Diabetol. 2021;20:193.
84. Shibata N, Morita Y, Ito T, et al. A machine learning algorithm for stratification of risk of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024;129:62-70.
85. Damluji AA, Alfaraidhy M, AlHajri N, et al. Sarcopenia and cardiovascular diseases. Circulation. 2023;147:1534-53.
86. López-Bueno R, Andersen LL, Koyanagi A, et al. Thresholds of handgrip strength for all-cause, cancer, and cardiovascular mortality: a systematic review with dose-response meta-analysis. Ageing Res Rev. 2022;82:101778.
87. Wu Y, Wang W, Liu T, Zhang D. Association of grip strength with risk of all-cause mortality, cardiovascular diseases, and cancer in community-dwelling populations: a meta-analysis of prospective cohort studies. J Am Med Dir Assoc. 2017;18:551.e17-35.
88. Lim TS, Kwon S, Bae SA, et al. Association between handgrip strength and cardiovascular disease risk in MASLD: a prospective study from UK biobank. J Cachexia Sarcopenia Muscle. 2025;16:e13757.
89. Nielsen RV, Fuster V, Bundgaard H, et al. Personalized intervention based on early detection of atherosclerosis: JACC state-of-the-art review. J Am Coll Cardiol. 2024;83:2112-27.
90. Kubotsu Y, Sakamoto Y, Tago M, et al. FIB-4 index and liver stiffness measurement are potential predictors of atherosclerosis in metabolic dysfunction-associated steatotic liver disease. J Atheroscler Thromb. 2025;32:239-52.
91. Zhang C, Ying Y, Ru Y, et al. Association between FIB-4 index and lower extremity arterial disease in MASLD patients: a cross-sectional study. Lipids Health Dis. 2025;24:103.
92. Bilson J, Mantovani A, Byrne CD, Targher G. Steatotic liver disease, MASLD and risk of chronic kidney disease. Diabetes Metab. 2024;50:101506.
94. Elshahat S, Cockwell P, Maxwell AP, Griffin M, O’Brien T, O’Neill C. The impact of chronic kidney disease on developed countries from a health economics perspective: a systematic scoping review. PLoS One. 2020;15:e0230512.
95. Hydes TJ, Kennedy OJ, Buchanan R, et al. The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank. BMC Med. 2023;21:185.
96. Sun Y, Hong L, Huang Z, et al. Fibrosis risk in nonalcoholic fatty liver disease is related to chronic kidney disease in older type 2 diabetes patients. J Clin Endocrinol Metab. 2022;107:e3661-9.
97. Bilson J, Hydes TJ, McDonnell D, et al. Impact of metabolic syndrome traits on kidney disease risk in individuals with MASLD: a UK biobank study. Liver Int. 2025;45:e16159.
98. Qi X, Li J, Caussy C, Teng GJ, Loomba R. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. Hepatology. 2026;83:661-78.
99. En Li Cho E, Ang CZ, Quek J, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72:2138-48.
100. Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2021;70:962-9.
101. Käräjämäki AJ, Bloigu R, Kauma H, et al. Non-alcoholic fatty liver disease with and without metabolic syndrome: Different long-term outcomes. Metabolism. 2017;66:55-63.
102. Souza M, Diaz I, Barchetta I, Mantovani A. Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Liver Int. 2024;44:6-14.
103. Iyer JS, Juyal D, Le Q, et al. AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases. Nat Med. 2024;30:2914-23.
104. Liu F, Goh GB, Tiniakos D, et al. qFIBS: an automated technique for quantitative evaluation of fibrosis, inflammation, ballooning, and steatosis in patients with nonalcoholic steatohepatitis. Hepatology. 2020;71:1953-66.
105. Jiang S, Li H, Zhang L, et al. Generic diagramming platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res. 2025;53:D1670-6.
106. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): executive summary. Diabetologia. 2024;67:2375-92.
107. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797-835.
108. Liang JX, Ampuero J, Niu H, et al. ; LITMUS Consortium Investigators. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. J Hepatol. 2023;79:592-604.
109. Castera L, Rinella ME, Tsochatzis EA. Noninvasive assessment of liver fibrosis. N Engl J Med. 2025;393:1715-29.
